SAB Biotherapeutics OverviewSAB Biotherapeutics Other Income Expense Net
Other Income/Expense Net for SABS.
Quarterly Other Income/Expense
$1.13M
↓ 79.75% YoY
As of Mar 31, 2026
Annual Other Income/Expense (TTM)
$57.78M
↑ 936.36% YoY
Trailing 12 months ending Mar 31, 2026